{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:00Z","timestamp":1792036860178,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese National Major Project for New Drug Innovation","award":["2019ZX09201002003"],"award-info":[{"award-number":["2019ZX09201002003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030076, 82070161, 81970151, 81670162 and 81870134"],"award-info":[{"award-number":["82030076, 82070161, 81970151, 81670162 and 81870134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Clinical Research Center for hematologic disease","award":["LCYSSQ20220823091401002"],"award-info":[{"award-number":["LCYSSQ20220823091401002"]}]},{"name":"Shenzhen Science and Technology Foundation","award":["JCYJ20190808163601776, JCYJ20200109113810154"],"award-info":[{"award-number":["JCYJ20190808163601776, JCYJ20200109113810154"]}]},{"name":"Shenzhen Key Laboratory","award":["ZDSYS20200811143757022"],"award-info":[{"award-number":["ZDSYS20200811143757022"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202111004"],"award-info":[{"award-number":["SZSM202111004"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Shenzhen University General Hospital","award":["SUGH2019QD012"],"award-info":[{"award-number":["SUGH2019QD012"]}]},{"name":"Shenzhen Natural Science Fund","award":["20200830182623001"],"award-info":[{"award-number":["20200830182623001"]}]},{"name":"HaiYa Young Scientist Foundation of Shenzhen University General Hospital","award":["HY002"],"award-info":[{"award-number":["HY002"]}]},{"name":"Shenzhen Medical Research Fund","award":["C2301003"],"award-info":[{"award-number":["C2301003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07106-w","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:26:46Z","timestamp":1762777606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-1823","authenticated-orcid":false,"given":"Chuling","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-2665","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"7106_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"7106_CR2","doi-asserted-by":"publisher","first-page":"E110","DOI":"10.1002\/ajh.25734","volume":"95","author":"A Godara","year":"2020","unstructured":"Godara A, Zhou P, Kugelmass A, Ma X, Rosenthal B, Toskic D, et al. Presence of soluble and cell-surface B-cell maturation antigen in systemic light-chain amyloidosis and its modulation by gamma-secretase inhibition. Am J Hematol. 2020;95(5):E110\u20133.","journal-title":"Am J Hematol"},{"issue":"8","key":"7106_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"7106_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"key":"7106_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"issue":"4","key":"7106_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"7106_CR7","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"7","key":"7106_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","volume":"108","author":"N Asherie","year":"2023","unstructured":"Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023;108(7):1827\u201339.","journal-title":"Haematologica"},{"issue":"5","key":"7106_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J, O\u2019Donnell EK, Raje N, Cook D, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023;7(5):768\u201377.","journal-title":"Blood Adv"},{"issue":"4","key":"7106_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"4","key":"7106_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3892\/etm.2023.12170","volume":"26","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ouyang C, Sun G, Liu H, Qi J, Suo X. Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma. Exp Ther Med. 2023;26(4):471.","journal-title":"Exp Ther Med"},{"issue":"9","key":"7106_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"issue":"6","key":"7106_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, et al. Karmma-rw: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11(6):116.","journal-title":"Blood Cancer J"},{"issue":"1","key":"7106_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"7106_CR15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868.","journal-title":"Nat Commun"},{"issue":"4","key":"7106_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"7106_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"7106_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688\u2013700.","journal-title":"Blood"},{"issue":"6","key":"7106_CR19","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"9","key":"7106_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30(9):695\u2013704.","journal-title":"Trends Cell Biol"},{"issue":"9","key":"7106_CR21","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848\u201359.","journal-title":"Nat Med"},{"issue":"7841","key":"7106_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-020-3032-z","volume":"589","author":"MA Willcockson","year":"2021","unstructured":"Willcockson MA, Healton SE, Weiss CN, Bartholdy BA, Botbol Y, Mishra LN, et al. H1 histones control the epigenetic landscape by local chromatin compaction. Nature. 2021;589(7841):293\u20138.","journal-title":"Nature"},{"issue":"7841","key":"7106_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","volume":"589","author":"N Yusufova","year":"2021","unstructured":"Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589(7841):299\u2013305.","journal-title":"Nature"},{"issue":"7","key":"7106_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40(7):768\u201386.","journal-title":"Cancer Cell"},{"issue":"8","key":"7106_CR25","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.molcel.2023.02.026","volume":"83","author":"E Battistello","year":"2023","unstructured":"Battistello E, Hixon KA, Comstock DE, Collings CK, Chen X, Rodriguez Hernaez J, et al. Stepwise activities of mSWI\/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Mol Cell. 2023;83(8):1216\u201336.","journal-title":"Mol Cell"},{"issue":"1","key":"7106_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","volume":"14","author":"N Jain","year":"2024","unstructured":"Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, et al. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function. Cancer Discov. 2024;14(1):142\u201357.","journal-title":"Cancer Discov"},{"issue":"7951","key":"7106_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"N Jain","year":"2023","unstructured":"Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. 2023;615(7951):315\u201322.","journal-title":"Nature"},{"issue":"620","key":"7106_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Zebley CC, Petersen CT, Fan Y, Anido AA, Yi Z, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13(620):eabh0272.","journal-title":"Sci Transl Med"},{"issue":"3","key":"7106_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41423-023-01118-6","volume":"21","author":"Y Li","year":"2024","unstructured":"Li Y, Han M, Wei H, Huang W, Chen Z, Zhang T, et al. Id2 epigenetically controls CD8(+) T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex. Cell Mol Immunol. 2024;21(3):292\u2013308.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"7106_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","volume":"30","author":"AK Mishra","year":"2024","unstructured":"Mishra AK, Schmidt TM, Martell EB, Chen AS, Dogru RE, Hematti P, et al. PD1(+)TIGIT(+)2B4(+)KLRG1(+) cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2024;30(2):191\u2013202.","journal-title":"Transplant Cell Ther"},{"key":"7106_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3861380","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, Li S, Zang Z, He Y. Yaobishu regulates inflammatory, metabolic, autophagic, and apoptosis pathways to attenuate lumbar disc herniation. Oxid Med Cell Longev. 2022;2022:3861380.","journal-title":"Oxid Med Cell Longev"},{"key":"7106_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216171","volume":"562","author":"Y Wan","year":"2023","unstructured":"Wan Y, Chen M, Li X, Han X, Zhong L, Xiao F, et al. Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma. Cancer Lett. 2023;562:216171.","journal-title":"Cancer Lett"},{"issue":"9","key":"7106_CR33","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, et al. Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy. Nat Med. 2022;28(9):1860\u201371.","journal-title":"Nat Med"},{"key":"7106_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 t cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301\u201318.","journal-title":"Annu Rev Med"},{"issue":"11","key":"7106_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion.\u2019 Nat Rev Immunol. 2019;19(11):665\u201374.","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07106-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:05:48Z","timestamp":1762884348000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07106-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7106"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07106-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Shenzhen University General Hospital and was registered with ClinicalTrials.gov (NCT05150522). Informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have obtained consent to publish from the participant to report patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1251"}}